PMID- 38112249
OWN - NLM
STAT- MEDLINE
DCOM- 20231225
LR  - 20240125
IS  - 1744-8395 (Electronic)
IS  - 1476-0584 (Linking)
VI  - 23
IP  - 1
DP  - 2024 Jan-Dec
TI  - Immunogenicity and safety of ebolavirus vaccines in healthy adults: a systematic 
      review and meta-analysis of randomized controlled trials.
PG  - 148-159
LID - 10.1080/14760584.2023.2296937 [doi]
AB  - BACKGROUND: This review aimed to systematically evaluate the immunogenicity and 
      safety of the candidate Ebola virus vaccine (EVV). METHODS: We searched five 
      databases for randomized controlled trials (RCTs) evaluating the effects of EVV 
      on healthy adults. The primary outcomes were relative risk (RR) of 
      sero-conversion or sero-response of EVV in healthy adults between the groups that 
      received EVV and the controls. RESULTS: Twenty-nine RCTs (n = 23573) were 
      included. There was a significant difference in RR of sero-conversion of EVV (RR 
      13.18; 95% CI 11.28-15.41; I(2) = 33%; P < 0.01) between the two groups. There 
      was a significant difference in RR of adverse events (AEs) of EVV (RR 1.49; 95% 
      CI 1.27-1.74; I(2) = 88%; P < 0.01), although no difference in RR of serious AE 
      (SAE) between the two groups. Subgroup analysis showed that there was no 
      significant difference in RR of AEs for DNAEBO, EBOV-GP, MVA, and rVSVN4CT1 
      vaccines, compared with controls. CONCLUSIONS: The DNAEBO, EBOV-GP, MVA, and 
      rVSVN4CT1 vaccines are likely to be safe and immunogenic, tending to support the 
      vaccination against Ebola disease. These findings should provide much-needed 
      evidence for public health policy makers to develop preventive measures based on 
      disease prevalence features and socio-economic conditions.
FAU - Yin, Juntao
AU  - Yin J
AD  - Department of Pharmacy, Huaihe Hospital, Henan University, Kaifeng, Henan, China.
AD  - National International Cooperation Base of Chinese Medicine, Henan University of 
      Chinese Medicine, zhengzhou, Henan, China.
FAU - Zhang, Liang
AU  - Zhang L
AD  - School of Medicine, Henan Technical Institute, Zhengzhou, China.
FAU - Wang, Chaoyang
AU  - Wang C
AD  - Department of General Surgery, Huaihe Hospital, Henan University, Kaifeng, Henan, 
      China.
FAU - Qin, Changjiang
AU  - Qin C
AD  - Department of General Surgery, Huaihe Hospital, Henan University, Kaifeng, Henan, 
      China.
FAU - Miao, Mingsan
AU  - Miao M
AD  - National International Cooperation Base of Chinese Medicine, Henan University of 
      Chinese Medicine, zhengzhou, Henan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20231222
PL  - England
TA  - Expert Rev Vaccines
JT  - Expert review of vaccines
JID - 101155475
RN  - 0 (Ebola Vaccines)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Ebola Vaccines/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - *Hemorrhagic Fever, Ebola/epidemiology/prevention & control
MH  - Vaccination
MH  - Antibody Formation
MH  - *Ebolavirus
OTO - NOTNLM
OT  - Ebola disease
OT  - Ebolavirus
OT  - immunogenicity
OT  - meta-analysis
OT  - safety
OT  - systematic review
OT  - vaccine
EDAT- 2023/12/19 19:54
MHDA- 2023/12/25 06:43
CRDT- 2023/12/19 07:52
PHST- 2023/12/25 06:43 [medline]
PHST- 2023/12/19 19:54 [pubmed]
PHST- 2023/12/19 07:52 [entrez]
AID - 10.1080/14760584.2023.2296937 [doi]
PST - ppublish
SO  - Expert Rev Vaccines. 2024 Jan-Dec;23(1):148-159. doi: 
      10.1080/14760584.2023.2296937. Epub 2023 Dec 22.